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Abstract
Background: Osteoporosis is a major health problem in postmenopausal women. Evidence
suggests the importance of oxidative stress in bone metabolism and bone loss. Tea consumption
may be beneficial to osteoporosis due to its antioxidant capability. However, lack of objective data
characterizing tea consumption has hindered the precise evaluation of the association between tea
ingestion and bone mineral density in previous questionnaire-based epidemiological studies. On the
other hand, although published studies suggest that Tai Chi (TC) exercise can benefit bone health
and may reduce oxidative stress, all studies were conducted using a relatively healthy older
population, instead of a high-risk one such as osteopenic postmenopausal women. Therefore, this
study was designed to test an intervention including green tea polyphenol (GTP) and TC exercise
for feasibility, and to quantitatively assess their individual and interactive effects on postmenopausal
women with osteopenia.
Methods/Design: One hundred and forty postmenopausal women with osteopenia (defined as
bone mineral density T-score at the spine and/or hip between 1 to 2.5 SD below the reference
database) were randomly assigned to 4 treatment arms: (1) placebo group receiving 500 mg
medicinal starch daily, (2) GTP group receiving 500 mg of GTP per day, (3) placebo+TC group
receiving both placebo treatment and TC training (60-minute group exercise, 3 times per week),
and (4) GTP+TC group receiving both GTP and TC training for 24 weeks. The outcome measures
were bone formation biomarker (serum bone alkaline phosphatase), bone resorption biomarker
(serum tartrate resistant acid phosphatase), and oxidative DNA damage biomarker (urinary 8-
hydroxy-2'-deoxyguanosine). All outcome measures were determined at baseline, 4, 12, and 24
weeks. Urinary and serum GTP concentrations were also determined at baseline, 4, 12, and 24
weeks for bioavailability. Liver function was monitored monthly for safety. A model of repeated
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BMC Musculoskeletal Disorders 2009, 10:110 http://www.biomedcentral.com/1471-2474/10/110measurements with random effect error terms was applied. Traditional procedures such as
ANCOVA, chi-squared analysis, and regression were used for comparisons.
Discussion: We present the rationale, design, and methodology of a placebo-controlled
randomized trial to investigate a new complementary and alternative medicine strategy featuring a
dietary supplement and a mind-body exercise for alleviating bone loss in osteopenic
postmenopausal women.
Trial registration: ClinicalTrials.gov identifier: NCT00625391
Background
Osteoporosis is a degenerative bone disease characterized
by low bone mass and structural deterioration of bone tis-
sue, leading to bone fragility and an increased susceptibil-
ity to fractures, especially of the hip, spine, and wrist [1].
Women are four times more likely to develop osteoporo-
sis than men because of a decrease in estrogen level after
menopause in conjunction with generally lighter and
thinner bones [2]. The rapid decrease in bone mineral
density (BMD) that occurs in the first 3 to 5 years imme-
diately following menopause, and the slower decrease
that continues throughout the remainder of a women's
life, markedly increase the risk of a hip or vertebral frac-
ture, which is a major cause of morbidity and mortality in
older women [1,2].
Osteoporosis is associated with many etiological causes,
such as poor nutrition, cytokines, hormones, and aging.
Reactive oxygen species (ROS) are considered to be
responsible for the aging process [3] and contributing to
etiology of various degenerative diseases, including oste-
oporosis [4-6]. It is believed that the rate of bone forma-
tion gradually diminishes, while the rate of bone
resorption is unaltered or accelerated with advancing age
in humans, resulting in net bone loss leading to the devel-
opment of osteoporosis. Estrogen is a phenolic com-
pound which enables it to detoxify accumulated ROS [7].
Thus, estrogen deficiency, which occurs after menopause,
leads to bone loss through increased osteoclastic function,
and represents the major pathological determinant
responsible for postmenopausal bone loss, as ROS stimu-
late osteoclasts that are responsible for bone resorption
[7,8].
There is evidence that ROS are involved in bone resorp-
tion with a direct contribution of osteoclast-generated
superoxide to bone degradation [9,10], and oxidative
stress increases differentiation and function of osteoclasts
[11]. In addition, osteoblasts produce antioxidants such
as glutathione peroxidase to protect against ROS [12], and
they also produce transforming growth factor-β, which is
involved in bone resorption [13]. Recent studies showed
that oxidative stress inhibited osteoblastic differentiation
[14] via extracellular signal-regulated kinases (ERK) and
ERK-dependent nuclear factor-κB signaling pathways [6].
A possible relationship between tea drinking and oste-
oporosis was suggested by a number of studies [15]. The
bioactive components in tea may benefit bone health in
terms of maintaining higher BMD [16-21] and reducing
fracture risk [22,23]. The health benefits of tea consump-
tion in preventing cancers and cardiovascular diseases
have been intensively investigated [24]. However, limited
information is available about the protective effect of con-
sumption of tea or its bioactive components on bone
health. These published results on BMD and tea con-
sumption were all based on cross-sectional studies or ret-
rospective studies and are, therefore, inconsistent [25],
which may compromise the quality of evidence.
The most widely recognized properties of tea polyphe-
nols, extract forms of tea, are their antioxidant activities,
arising from their ability to scavenge ROS [26]. Tea
polyphenols also bind to metal ions, preventing these
ions from participating in peroxidative reactions. Green
and black tea and isolated tea polyphenols have been
shown to scavenge reactive oxygen and nitrogen species,
and to reduce their damage to lipid membranes, proteins
and nucleic acids in cell-free systems [26]. Among differ-
ent green tea components, green tea polyphenols (GTP)
have been shown to be safe and to have many beneficial
health effects in various human populations [27]. Several
mechanisms have been proposed for the osteo-protective
effect of GTP including decreasing oxidative stress [28,29],
increasing activity of antioxidant enzymes [28], and
decreasing expression of proinflammatory mediators
[28,29] in rodent models.
However, no study has ever been conducted to show the
antioxidant role of GTP in bone metabolism of postmen-
opausal women with low bone mass.
Exercise has been shown to benefit osteoporosis by reduc-
ing bone loss. Numerous studies have reported the effectPage 2 of 10
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women with or without osteopenia/osteoporosis [30-32].
Tai Chi (TC) exercise has gained much attention recently
in the rehabilitation and geriatric community [32-35].
The systematic study of TC's effect on bone mass, how-
ever, is limited. A case-control study conducted in post-
menopausal Chinese women in Hong Kong showed that
women having done TC for more than 4 years had signif-
icantly higher BMD in the lumbar spine, proximal femur,
and ultradistal tibia than non-exercising women [32].
Their 12-month (without intervention) follow-up meas-
urement showed generalized bone loss in both groups,
but the TC exercisers had a significantly slower decrease in
BMD than the non-exercising group. A longitudinal study
showed that 12 months of 108-form TC decelerated bone
loss in early postmenopausal women compared to seden-
tary controls [35]. A cross-sectional study revealed that
regular TC exercise may be associated with higher BMD
[32] in early postmenopausal women than in sedentary
controls [34]. Among these previous studies, there was
only one longitudinal study [35], but that study did not
target a high-risk population (osteopenia or osteoporo-
sis). Besides, that study employed a complicated 108-
form TC, which was difficult for the U.S. population to
learn. The two previous cross-sectional studies [32,35]
could not identify the type of TC (among dozens currently
being practiced worldwide) that had been practiced by the
women included in the study.
Exercise can have positive or negative effects on oxidative
stress depending on training load, training specificity and
the basal level of training [36]. High-intensity exercise
increases oxidative stress, whereas moderate exercise
tended to decrease oxidative stress [37]. TC has been char-
acterized as an exercise of moderate intensity [38,39]. TC
couples muscular activity with an internally directed
focus, producing a temporary self-contemplative mental
state. Such internal focus is in contrast to conventional
body-centered aerobic and muscular fitness exercise, in
which there is little or no mindful component [40]. More-
over, both TC and Yoga are considered as mind-body exer-
cise [41], and both of these have been used as mind-body
therapies in the treatment of musculoskeletal disorders
with implications for the elderly [41]. Yoga has been dem-
onstrated to reduce oxidative stress by showing a signifi-
cantly lower level of free radicals and a higher level of
superoxide dismutase in blood compared to the sedentary
control [42]. However, no study has demonstrated the
effect of TC on oxidative stress.
Therefore, the objective of the present study was to test
complementary and alternative medicine interventions
including GTP and TC exercise for feasibility, and to quan-
titatively assess their individual and interactive effects on
osteopenic postmenopausal women. We hypothesized
that 24 weeks of GTP supplement, TC exercise, and their
combination would benefit bone remodeling, as meas-
ured by bone biomarkers in postmenopausal women with
osteopenia, compared to those receiving placebo only,
and the changes in bone biomarkers associated with bone
remodeling would be correlated with the changes in oxi-
dative stress. This hypothesis was based on the premise
that both TC and GTP may reduce oxidative stress, and
that oxidative stress has been demonstrated to adversely
affect bone health by both increasing differentiation and
function of osteoclasts [11] and inhibiting osteoblastic
differentiation [14].
In this paper, we present the design and detailed protocol
of a placebo-controlled and randomized trial, as well as a
discussion of the overall challenges of conducting this
trial. The results from this trial will be reported at the com-
pletion of the study in accordance with the Consolidation
of Standards for Reporting Trials guidelines [43].
Methods/Design
Study design
The combination of dietary supplement and moderate
intensity exercise now becomes a new strategy in alleviat-
ing bone loss in postmenopausal women with low bone
mass, due to the possible synergistic effects of the combi-
nation.
This was a 24-week placebo-controlled and randomized
intervention trial to investigate the effects of GTP and TC
on relevant primary and secondary endpoints in postmen-
opausal women with osteopenia. Women at least 2 years
after menopause, with osteopenia, were recruited prima-
rily from local senior independent/assisted living facili-
ties, municipal senior community centers, and obstetrics
and gynecology clinics. An initial sample size of 140 par-
ticipants with an expected attrition rate of 15% over 24
weeks of intervention produced a final sample size of 120
participants. This sample size yielded a power of approxi-
mately 0.85 to 0.9 at α = 0.05 for detecting differences in
primary and secondary outcome measures. After screen-
ing, qualified participants were matched for age and were
randomly assigned to one of the four treatment groups:
placebo, GTP, placebo+TC, and GTP+TC. During the 24-
week intervention, all participants were provided with
500 mg elemental calcium and 200 IU vitamin Ddaily.
The participants in the placebo group received 250-mg
capsules of medicinal starch, 2 per day for 24 weeks. The
GTP participants received 250-mg capsules of GTP, 2 per
day for 24 weeks. The placebo+TC participants received
both placebo and TC intervention (60-minute TC group
class, 3 times per week) for 24 weeks. The GTP+TC partic-
ipants received both GTP and TC intervention for 24
weeks. Participants received the primary and secondary
outcome measures at baseline, 4, 12, and 24 weeks. ThePage 3 of 10
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ers (serum bone-specific alkaline phosphatase, BAP and
serum tartrate-resistant acid phosphatase, TRAP) and a
biomarker of oxidative stress DNA damage (urinary 8-
OHdG concentration). Urinary and serum GTP concen-
trations were determined at baseline, 4, 12, and 24 weeks.
Liver function was also monitored monthly by assessing
the activity of aspartate aminotransferase (AST) and
alanine aminotransferase (ALT). Investigators evaluating
the endpoints were blinded to intervention allocation.
(See Study Flow Chart in Figure 1). The study has received
Ethics approval from the Texas Tech University Health Sci-
ences Center Institutional Review Board.
Study population and recruitment
The present study was conducted in Lubbock, Texas and
the surrounding area. This study consisted of women at
least 2 years after menopause, ambulatory, irrespective of
ethnicity/race, primarily recruited from local clinics,
municipal senior community centers, and health fairs.
Study flow chartFigure 1
Study flow chart.
Division of Clinical Research 
(pre-phone screening)
Local specialty clinics (n=xxx)




TV, radio, newspaper, 
flyers, e-mail (n=xxx)




Placebo + TC (n=35)
500 mg starch/d, 
60 min TC, 3x/wk for 24 wk
GTP + TC (n=35)
500 mg GTP/d, 
60 min TC, 3x/wk for 24 wk
GTP (n=35)
500 mg GTP/d 
for 24 wk
Placebo (n=35)
500 mg starch/d 
for 24 wk
Refuse to participate (n=xxx)
Refuse to participate (n=xxx)
Dropout (n=xx)
Baseline measurements  (n=xxx)
(serum BAP, serum TRAP, urinary 8-OHdG)
4-wk follow-up measurements (n=xxx)
(serum BAP, serum TRAP, urinary 8-OHdG)
Dropout (n=xx)
Dropout (n=xx)
24-wk follow-up measurements (n=xxx)
(serum BAP, serum TRAP, urinary 8-OHdG)
Dropout (n=xx)
12-wk follow-up measurements (n=xxx)
(serum BAP, serum TRAP, urinary 8-OHdG)
Ineligible (n=xxx)Page 4 of 10
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ior newsletters/family magazines, flyers, and posters also
proved to be very effective as an initial recruiting strategy.
Screening
Assessment of potential participants involved a brief sur-
vey on menstrual history, medical history, availability for
the study period, most recent BMD result if available, any
existing bone metabolic diseases, etc., conducted over the
phone by nurse research coordinators. This pre-screening
procedure identified the potential participants who were
interested in the research and were qualified for further
screening. After telephone pre-screening, potential sub-
jects were invited to attend an informed consent session.
After signing consents and Health Insurance Portability
and Accountability Act (HIPAA) forms, participants com-
pleted a detailed questionnaire that was developed to col-
lect demographic, health, and dietary information. Then,
the potential participants were invited for bone density
screening and fasting blood screening visits.
Inclusion criteria
1. Women at least 2 years after menopause with oste-
openia [44]. Osteopenia was defined as bone mineral
density T-score at the spine and/or hip between 1 to
2.5 SD below the young normal xex-mateched areal
BMD of the reference database [44].
2. Normal function of thyroid, liver, and kidney.
3. Serum 25-hydroxy vitamin D ≥ 20 ng/mL.
Exclusion criteria
1. History of metabolic bone diseases or treatments
that might influence bone turnover.
2. History of cancer except for superficial basal or
squamous cell carcinoma of the skin that was treated,
and other malignancies treated at least 5 years ago
without any evidence of recurrence.
3. Uncontrolled intercurrent illness or physical condi-
tion that would be a contraindication to exercise.
4. Cognitive impairment as defined as Mini-Mental
State Examination score of 24 or less [45].
5. Depression as defined as Yesavage self-rated Geriat-
ric Depression Scale score at least 11 [46].
6. Unwilling to accept randomization.
Sample size
Data from previous studies by our team [47,48] were used
for the calculation of the minimum sample size. The out-
come measures were serum BAP [47], serum TRAP, and
urinary 8-OHdG [48]. The baseline measurements for
control (placebo) and intervention groups (GTP, pla-
cebo+TC, GTP+TC) were assumed to be the same as the
values in the previous studies. Intervention groups were
expected to exhibit changes in outcome measures in the
follow-up by a certain percentage (10% increase, 10%
decrease, and 20% decrease for BAP, TRAP, and 8-OHdG,
respectively), while the placebo group was expected to
exhibit no changes throughout the study. In the power
analysis, it was further assumed that the correlation
between baseline and the follow-up measurements was
0.85, and the correlation between the follow-up measure-
ments was 0.95. A balanced sample, viz. same sample size
for the control and intervention groups, was obtained.
The main comparisons were expected to be made as fol-
lows: placebo vs. GTP; placebo vs. placebo+TC; and pla-
cebo vs. GTP+TC. Therefore, a sample size of 30 for each
group was needed. Taking into consideration an expected
attrition rate of 15%, N = 35 were recruited for each group,
or a total of 140 participants to start the study.
Randomization
All participants who had passed the screening criteria par-
ticipated in randomization where participants were
assigned to one of the 4 treatment arms with a fixed rand-
omized scheme. In order to minimize the consequent
bias, a stratified randomization method was employed
based on age (>65 or <65 years old), history of green tea
consumption, and history of mind-body exercise to assign
participants to placebo, GTP, placebo+TC, or GTP+TC
group.
Intervention
Purchasing and masking of study agents
Placebo and GTP of the same lot, respectively, were pur-
chased from Zhejiang Yuxin Pharmaceutical Co., Ltd.,
China (IND no. 77,470 by FDA). Each placebo capsule of
250 mg medicinal starch contained no GTP ingredient at
detectable levels. Each GTP capsule contained 250 mg
GTP ingredient [46.5% of epigallocatechin-3-gallate
(EGCG), 21.25% of epigallocatechin (ECG), 10% of epi-
catechin (EC), 7.5% of epicatechin-3-gallate (EGC), 9.5%
of gallocatechin gallate (GCG), and 4.5% of catechin] and
the purity was higher than 98.5%. The use of placebo for
masking the control group was desirable in this study to
keep respondents blinded to the GTP treatment assign-
ment. Placebo capsules were made of the same size and
color as the GTP capsule. The placebo group provided a
comparison of blood and urinary outcome measures and
served as a basis to assess GTP's effect.
Provision of calcium plus vitamin D supplement
Calcium (500 mg elemental Ca, as Oyster Shell)/vitamin
D (200 IU as cholecalcifero) supplement daily was pro-Page 5 of 10
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Ca/vitamin D intake is essential for realizing the benefi-
cial effects of dietary supplements and exercise on BMD
[49,50]. According to reported data, the calcium intake for
our target population was about 700 to 800 mg daily
[51,52]. Our goal was to supplement our subjects with
additional elemental calcium (500 mg) in order to ensure
that they receive total recommended calcium of 1000 mg-
1500 mg. Similarly, the vitamin D supplementation we
provided was to complement what the subjects were
assumed to have received from diet and sun exposure, in
order to reach the total daily recommendation. Therefore,
if we had provided Ca/vitamin D at a higher dose, the
potential effect of GTP may have been masked, due to Ca/
vitamin D's strong anti-resorptive effect.
Treatment arms
The present study had four intervention groups, placebo,
GTP, placebo+TC, and GTP+TC. Provision of placebo to
the control and TC only groups increased the accuracy of
the interventions, since it kept respondents blinded to the
GTP treatment assignment. Participants in the placebo
treatment group were provided 500 mg of medicinal
starch daily for 24 weeks. Participants were instructed to
take 1 capsule containing 250 mg in the morning and
another 1 capsule in the evening, after meals. Similar to
those in the placebo treatment group, participants in the
GTP treatment group were provided 500 mg (250 mg cap-
sule × 2 per day) of GTP per day for 24 weeks. Participants
in placebo+ TC group received placebo treatment and TC
training for 24 weeks. In addition to 500 mg of medicinal
startch daily, the TC training was held at the exercise hall
of a local community center, for 60 minutes three times a
week (on three nonconsecutive days), for 24 weeks. Each
training session consisted of 10 minutes of warm-up exer-
cise, 40 minutes of TC, and 10 minutes of cool-down exer-
cise. The warm-up exercise featured movements of all
major body joints that were involved in the subsequent
TC exercise. Participants were taught by a qualified
instructor the 24-move simplified Yang-style TC [120] for
40 minutes during each session. The cool-down exercise
involved whole body relaxation and deep breathing.
Make-up sessions were offered to participants if necessary.
Participants in the GTP+TC group received both GTP
treatment and TC training for 24 weeks.
Dietary Intake, Physical Activity, and Concomitant 
Medication Assessment
A complete and accurate dietary assessment was needed to
determine whether drastic dietary changes occurred dur-
ing the intervention period that could affect outcome
measures. A 3-day dietary intake log was collected at the
baseline, mid, and final visits and analyzed by Nutrition-
ist Pro (First Data Bank, Inc., CA) to determine usual die-
tary intake (including specific macro- and micro-
nutrients) over time and deviations from baseline. A phys-
ical activity log was collected at the baseline, mid, and
final visits to record any deviation from the usual activi-
ties. Concomitant medications/therapies (including over
the counter and dietary supplements) were documented,
including drug name and the reason for the medication/
therapies throughout the study period.
Blinding/unblinding
All investigators, measurement and site personnel were
blinded throughout this study. However, it was impossi-
ble to keep the TC instructor and the pharmacist, who dis-
tributed placebo or GTP capsules, blinded. Investigators
evaluating the endpoints were blinded to intervention
allocation.
Sample collection
Fasting blood and urine samples (morning after first
empty of the bladder) were collected for both primary and
secondary outcome measures. Blood was drawn from a
superficial arm vein with a syringe, transferred to a vacu-
tainer, allowed to clot at room temperature, centrifuged at
1500× g for 10 min within 2 hr of collection, and aliq-
uoted from each collection. During the visit for blood
sample collection, urine samples were also collected in
acid-washed polyethylene containers. Urine was aliq-
uoted from each collection. All aliquoted blood and urine
samples were stored in -80°C freezers prior to biochemi-
cal analyses.
Evaluation of Adherence
Adherence to the intervention was evaluated by monitor-
ing the consumption of capsules by pill count and attend-
ance at TC training sessions. Compliance was determined
as the percentage of all capsules ingested or possible
group classes attended. The TC class attendance record
was kept for each participant in the placebo+TC and
GTP+TC groups.
Evaluation of Adverse Events
Adverse effects associated with placebo or GTP treatment
were self-reported by the participants if any, and by mon-
itoring liver function monthly in the course of the inter-
vention trial. Participants in the placebo+TC and the
GTP+TC groups were also queried about any adverse
events during TC training sessions by self-reported phone
calls. All observed or volunteered adverse events, regard-
less of suspected causal relationship to the study treat-
ments, were recorded on the adverse event form
throughout the study.
Measurements
Every participant was evaluated at baseline (prior to start-
ing intervention), 4, 12, and 24 weeks of intervention.Page 6 of 10
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Rationale
Biochemical markers of bone turnover have been shown
to be promising in predicting fractures in the elderly up to
2 years before the event [53]. Assessing serum BAP (a bone
formation biomarker) and serum TRAP (a bone resorp-
tion biomarker) could provide a more thorough clinical
evaluation of bone status than BMD in predicting skeletal
response to an exercise program and in monitoring bone
resorption changes following initiation of exercise as early
as month 3 [54].
Methods
The concentration of bone formation biomarker, BAP, in
serum was measured using Metra™ BAP immunoassay kits
(Quidel Corporation, San Diego, CA). The intra-assay CV
of the BAP assay was 5.2%, and the inter-assay CV was
5.0%. Such procedures are routinely performed in our
laboratory [47]. The concentration of bone resorption
biomarker, TRAP, in serum was quantified using a com-
mercial kit with a monoclonal antibody specific for the
serum band 5 tartrate-resistant acid phosphatase (Micro-
Vue™ TRAP5b, Quidel). The intra-assay variability was
2.2% CV and inter-assay variability was 3.0% CV. In order
to avoid the interassay variation, the samples from base-
line, 4, 12, and 24 week visits of the same patients were




When ROS attack all macromolecules including lipids,
proteins, and DNA, the addition of the hydroxyl group (-
OH) to the C8-position of guanine produces C8-OH-
adduct radical [55], which is subsequently converted to 8-
OH-Guanine (8-OH-Gua) by a one-electron oxidation
[56]. While damaged lipids and proteins can be removed
by metabolic turnover of molecules, impaired DNA has to
be repaired in situ, or destroyed by apoptotic processes, if
not to result in mutations. In humans, 8-OH-Glu glycosy-
lase is the primary enzyme for the repair of 8-OH-Gua in
a short-patch base-excision repair [57]. The excised form
of 8-OH-Gua is 8-OHdG is excreted into urine without
further metabolism and is stable for a significant time.
Thus, urinary 8-OHdG generally reflects the whole body's
oxidative DNA damage and repair, and becomes a puta-
tive biomarker for oxidative stress [58]. Detection of uri-
nary 8-OHdG provides a sensitive and non-invasive
means to evaluate the efficacy of dietary antioxidant sup-
plements, such as GTP. We measured urinary 8-OHdG
levels in this study to evaluate the effect of treatments.
Methods
The concentration of 8-OHdG, DNA damage oxidative
stress biomarker, in urine was determined [48]. The uri-
nary 8-OHdG was extracted from 1 ml urine with the
Oasis® HLB 3 cc (60 mg) cartridge. The eluents were dried
under ultra-pure N2 stream and reconstituted in buffer (10
mM ammonium acetate in 2% MeOH, pH 4.3) for analy-
sis with the ESA HPLC-CoulArray system. The system con-
sisted of double Solvent Delivery Modules (Model 582
pump), Autosampler (Model 542) with 4°C cool sample
tray and column oven, CoulArray Electrochemical Detec-
tor (Model 5600A), and an Operating Computer. The
HPLC column for 8-OHdG analysis was the Waters YMC
basic™ column (S3 μm, 4.6 × 150 mm). The mobile phase
consisted of buffer A (10 mM ammonium acetate, pH 4.3)
and buffer B (methanol). Flow rate was kept at 0.8 ml/
min and a linear gradient (0-40% MeOH in 15 min) was
applied for chromatographic separation with the peak of
8-OHdG eluted at around 9.5 min. The CoulArray Detec-
tor was set at 270, 300, 330, and 360 mv; the highest peak
appeared at 330 mv channel. Authentic standard 8-OHdG
was used for qualification by retention times and response
patterns, and quantification by calibration curves. The
limit of detection for 8-OHdG was 1 ng/ml urine. The
amount of 8-OHdG was adjusted by urinary creatinine
level. Urinary creatinine level was determined colorimet-
rically with a Diagnostics Creatinine Kit (Sigma Co).
Absorbance at 500 nm was recorded by a DU640 VIS/UV
spectrophotometer [48].
Serum and Urinary GTP concentration
Rationale
The bioavailability of GTP was considered when we quan-
titatively evaluated the biological effects of GTP interven-
tion. Therefore, we planed to measure the GTP levels in
biofluid, such as serum and urine, of participants at base-
line, 4, 12, and 24 weeks.
Methods
The procedures for analyzing serum and urinary GTP con-
jugates were modified from established protocols [48,59].
Briefly, serum (200 μL) or urine (500 μL) samples were
incubated without enzyme, with betaglucuronidase (500
units for serum and 200 units for urine) or with 40-units
of sulfatase at 37°C simultaneously for 1 h, to generate
free GTP, free plus glucuronidated GTPs, free plus sulfated
GTPs, and methylated GTPs, respectively. The extracted
samples were vacuum-dried and reconstituted for HPLC-
CoulArray analysis.
The HPLC-CoulArray system consists of double Solvent
Delivery Modules (Model 582 pump), Autosampler
(Model 542) with 4°C cool sample tray and column oven,
CoulArray Electrochemical Detector (Model 5600A), and
an Operating Computer. The HPLC column was an Agi-
lent Zorbax reverse-phase column, Eclipse XDB-C18 (5μm, 4.6 × 250 mm). The mobile phase included buffer A
(30 mM NaH2PO4/ACN/THF = 98/1.8/0.2, pH 3.35) andPage 7 of 10
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3.45). Flow rate was set at 1 ml/min and the gradient
started from 4% buffer B, to 24% B at 24 min, to 95% B at
35 min, kept at 95% until 42 min, dropped to 4% at 50
min, and maintained at 4% until 59 min. Authentic
standards were prepared with ascorbic acid.
Calibration curves for individual GTP components were
generated separately, and EGC, EC, EGCG and ECG were
eluted at around 14, 21, 24 and 29 min, respectively. The
electrochemical detector was set at -90, -10, 70 and 150
mV potentials, with the main peaks appearing at -10 mV
(EGC), 70 mV (EC, EGCG) and 150 mV (ECG). Quality
assurance and quality control procedures were taken dur-
ing analyses, including analysis of authentic standards for
every set of five samples and simultaneous analysis of
spiked urine sample daily. The limits of detection were 0.5
ng/mL urine for EC, EGC, and methylated-EGC; and 0.5
ng/mL plasma for EGCG, ECG, and dimethylated-EGCG,
respectively. The levels of glucuronidated or sulfated GTP
or methylated GTP were calculated by subtraction of free
GTP levels from corresponding digestions. The four forms
of GTP were pooled as a total for calculation of conjuga-
tion percentiles.
Statistical Analysis
Due to the longitudinal design of the proposed study, a
model of repeated measurements with random effect
error terms was used. Statistical software SAS was
employed to conduct the analyses, controlling for the
within subject correlation. First, the measurements were
compared across the 4 groups at the baseline. In addition,
participant characteristics were compared to detect
whether participants in these four groups were different in
certain characteristics. Second, the changes in the meas-
urements from baseline to the follow-ups were calculated
for each group. We then tested whether these changes
were statistically significant. Time-dependent trends, if
any, were identified. For between-group differences, a
two-way ANCOVA (TC and GTP) was conducted and con-
trolled for within-subject correlation. To control for the
effect of age, body mass index, BMD, and other covariates
(i.e., years after menopause, prior meditation and mind-
body exercise exposure, habit of green tea consumption,
etc), a multivariate ANCOVA was also performed. Third,
the characteristics of participants who dropped out were
compared with those of the participants who stayed for
the entire study period, in order to detect potential biases.
Discussion
We have presented the rationale, design, and methodol-
ogy of a placebo-controlled randomized trial, with quan-
titative studies, to investigate a new complementary and
alternative medicine strategy featuring a dietary supple-
ment and a mind-body exercise for alleviating bone loss
in postmenopausal women with low bone mass. The
results of this research will be presented as soon as they
are available.
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